Login
$CRBU
$0.36 +$0.01 (1.7%) After hours

$CRBU SEC Filings

Filed On Filing
05 Nov 2026 10-Q
05 Nov 2026 8-K: Results of Operations and Financial Condition

BERKELEY, Calif., November 5, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU) today reported financial results for the third quarter of 2026.

06 Oct 2026 8-K: Costs Associated with Exit or Disposal Activities; Departure/Election of Directors or Officers; Compensation +2 more

— Company to evaluate strategic alternatives to maximize stockholder value —

13 Aug 2026 10-Q
13 Aug 2026 8-K: Results of Operations and Financial Condition

-- ANTLER phase 1 data presented at EHA 2026 reinforce vispa-cel safety, efficacy, and durability are on par with approved autologous CAR-T cell therapies and that vispa-cel has the potential to overcome access barriers for patients with...

27 Jul 2026 SCHEDULE 13G
18 Jun 2026 8-K: Submission of Matters to a Vote of Security Holders

On June 17, 2026, Caribou Biosciences, Inc. (the “Company”) held its annual meeting of stockholders (the “Annual Meeting”). The final results for each of the proposals submitted to a vote of the Company’s stockholders at the Annual Meeti...

11 Jun 2026 8-K: Regulation FD Disclosure; Other Events

Caribou Biosciences Reports Dose Escalation Durability Data for CB-011 at the 2026 European Hematology Association (EHA) Annual Meeting

05 Jun 2026 DEFA14A
07 May 2026 10-Q
07 May 2026 8-K: Results of Operations and Financial Condition

-- Achieved alignment with FDA on pivotal ANTLER-3 trial design for vispa-cel in 2L LBCL --

01 May 2026 DEFR14A
24 Apr 2026 ARS
24 Apr 2026 DEFA14A
24 Apr 2026 Proxy statement: annual meeting on June 17, 2026
10 Apr 2026 PRE 14A
31 Mar 2026 8-K: Regulation FD Disclosure; Other Events

Caribou Biosciences Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) Designation to CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy

05 Mar 2026 S-8
05 Mar 2026 10-K
05 Mar 2026 8-K: Results of Operations and Financial Condition

BERKELEY, Calif., March 5, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today reported financial results for fourth quarter and full year 202...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support